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Fasting Serum C-Peptide Levels Predict Cardiovascular and Overall
Death in Nondiabetic Adults
Nileshkumar Patel, MD; Tracey H. Taveira, PharmD; Gaurav Choudhary, MD; Hilary Whitlatch, MD; Wen-Chih Wu, MD, MPH
Background-—Insulin resistance, characterized by hyperinsulinemia and normal or elevated serum glucose, is an established
precursor to diabetes and cardiovascular disease. Despite fasting serum C-peptide levels being an accurate and stable marker of
endogenous insulin production used in patients with diabetes, it is unknown whether C-peptide could serve as a marker of insulin
resistance and predict outcomes in patients without diabetes.
Method and Results-—This is a retrospective cohort study using data from the NHANES-3 (1988–1994) survey with mortality
follow-up through December 31, 2006. Participants included 5153 subjects, 40 to 74 years of age with fasting glucose ≥70 mg/
dL, without diabetes by history or laboratory testing. Receiver-operating-curve analysis compared fasting C-peptide against known
insulin resistance measures such as fasting plasma glucose, serum insulin, HOMA-IR, quantitative-insulin-sensitivity-check-index,
and metabolic syndrome for the prediction of cardiovascular and overall death. Subjects were then stratiﬁed by quartiles of
C-peptide levels. Cox proportional-hazards modeling compared hazards of cardiovascular and overall death amongst C-peptide
quartiles and adjusted for potential confounders of cardiovascular and diabetes risk. Fasting serum C-peptide levels predicted
cardiovascular and overall death better than other studied measures (AUC=0.62 and 0.60 respectively vs the rest, with AUC≤0.58
and ≤0.57 respectively, P<0.001). When compared with the lowest C-peptide quartile, subjects in the highest quartile had
signiﬁcantly higher adjusted hazard ratios (HR) of cardiovascular death (HR=1.60, 95%CI 1.07 to 2.39) and overall mortality
(HR=1.72, 95%CI 1.34 to 2.21) after controlling for confounders.
Conclusions-—C-peptide levels signiﬁcantly related to hazards of cardiovascular and overall death in nondiabetic adults and was a
better predictor of these outcomes than serum insulin and/or glucose derived measures. ( J Am Heart Assoc. 2012;1:e003152
doi: 10.1161/JAHA.112.003152)
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I nsulin resistance is a component of type 2 diabetes
1 and is
associated with obesity2 and glucose, lipid and blood
pressure dysregulation,3 in a conglomeration of cardiovascu-
lar risk factors deﬁned as metabolic syndrome.4,5 Insulin
resistance is characterized by hyperinsulinemia6 in the setting
of normal or elevated serum glucose and has been related to
incident diabetes,7 coronary heart disease,8,9 and mortal-
ity10,11 in subgroups of nondiabetic subjects. Therefore,
assessment of insulin resistance is an important way to
identify individuals without diabetes who are at an increased
risk for adverse outcomes and potentially targets them for
early intervention.
Previous studies have included measurement of serum
insulin levels as a marker of insulin resistance.7 An alternative
marker is C-peptide, a protein that is cosecreted with insulin
on an equimolar basis from pancreatic beta cells. Unlike
insulin, it does not undergo hepatic ﬁrst pass metabolism, has
a longer half-life, and has been recognized as a more stable
and accurate marker of endogenous insulin secretion.12–14
However, there is limited data on the clinical and epidemi-
ological value of C-peptide measurement as a marker of
insulin resistance, especially in individuals without known
diabetes mellitus. Furthermore, it is unclear how C-peptide
compares to other known indices of insulin resistance in
predicting cardiovascular and overall death.
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We hypothesized that fasting serum C-peptide level is a
better marker of insulin resistance than insulin level alone and
would be useful in the prediction of death related to
cardiovascular disease in adults without diabetes. To test
this hypothesis, we compared fasting serum C-peptide level to
other measures of insulin resistance as a predictor of future
cardiovascular and overall death using biochemical and
outcome data from a nationally representative sample of
nondiabetic adults living in the United States. Additionally, we
studied the relationship between C-peptide levels and mor-
tality related to cardiovascular diseases, independent of other
known cardiovascular or diabetes risk factors.
Methods
Design
We conducted a retrospective cohort study to assess the
relationship between insulin resistance as measured by
fasting C-peptide levels and subsequent cardiovascular
disease and overall death in nondiabetic adults.
Data Source
The Third National Health and Nutrition Examination Survey
(NHANES 3) was a nationwide survey conducted by the
Centers for Disease Control and Prevention to assess the
health and nutrition status of adults and children in the United
States in 1988–1994 through interviews, physical examina-
tion, and laboratory assessments.15 Because this study
involved the use of deidentiﬁed data in a publically accessible
government database, we obtained an exemption status from
the Providence VA Medical Center’s institutional review board.
Study Sample
We studied adults without diabetes, 40 to 74 years of age,
who had undergone an oral glucose tolerance test from the
NHANES 3 data set (N=6652). Excluded were participants
who were told they had diabetes by their physicians or were
taking antidiabetes medications (510 excluded) and those
who had a fasting plasma glucose ≥126 or <70 mg/dL, an
oral glucose tolerance test glucose ≥200 mg/dL, or serum
hemoglobin A1c levels of ≥6.5% (989 excluded). This yielded a
ﬁnal analytic sample of 5153 subjects.
Outcomes
The primary outcome was cardiovascular death, and the
secondary outcome was overall (all-cause) death. Tertiary
outcomes included subcategories of the primary outcome
such as cerebrovascular disease death, ischemic heart
disease death, and myocardial infarction death. Mortality
status was obtained from the NHANES 3–linked mortality-
public-use ﬁle, which provided mortality data from the date
of the NHANES 3 survey participation through December
31, 2006.15 Underlying causes of death were provided by
death certiﬁcate data contained in the same mortality ﬁles
and classiﬁed according to the 10th International Statistical
Classiﬁcation of Diseases, Injuries and Causes of Death
(ICD-10) guidelines. Cardiovascular death was considered
when cardiovascular disease was the underlying cause of
death or when it is one of the multiple causes of the death.
The ICD-10 codes for cardiovascular disease (I00 to I99)
were identiﬁed according to the American Heart Association
guidelines and included essential hypertension and hyper-
tensive heart and kidney disease (I10 to I13), ischemic
heart diseases (I20 to I25), acute rheumatic fever and
chronic rheumatic heart diseases (I00 to I09), acute and
subacute endocarditis (I33), diseases of pericardium and
acute myocarditis (I30 to I31, I40), other heart diseases
(I26 to I51), heart failure (I50), all other forms of heart
disease (I26 to I28, I34 to I38, I42 to I49, I51),
cerebrovascular diseases (I60 to I69), atherosclerosis
(I70), and other diseases and disorders of circulatory
system (I71 to I78, I80 to I99).16 The distribution of major
cardiovascular diseases in death certiﬁcates of the study
population was included in Table 1. Follow-up data were
99.8% complete, with the exception of 1 participant without
Table 1. Distribution of Major Cardiovascular Diseases in
Death Certiﬁcates of the Study Population
Ischemic heart diseases, % 50.6
Cerebrovascular diseases, % 14.84
Hypertension as multiple causes of death, % 8.74
Hypertensive heart disease, % 2.64
Hypertensive heart and renal disease, % 0.41
Essential (primary) hypertension and hypertensive
renal disease, %
1.83
Heart failure, % 5.89
Aortic aneurysm and dissection, % 2.24
Other diseases of arteries, arterioles and capillaries, % 0.20
Other disorders of circulatory system, % 0.81
Atherosclerosis, % 0.81
All other forms of heart disease*, % 10.37
Acute rheumatic fever and chronic rheumatic heart
diseases, %
0.41
Acute and subacute endocarditis, % 0.20
*Pulmonary heart disease and diseases of pulmonary circulation (eg, pulmonary
embolism), valvular heart disease, cardiomyopathy, arrhythmia (tachy and brady), cardiac
septal disease, rupture of chordae tendinae, myocarditis, myocardial degeneration, and
Takotsubo syndrome.
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survival data and 12 participants whose underlying cause of
death cannot be ascertained because death certiﬁcate data
were not available.
Fasting serum C-peptide levels were drawn in conjunction
with baseline plasma glucose as part of the participant’s oral
glucose tolerance test and excluded participants with any of
the following conditions: diagnosis of diabetes mellitus,
prescribed medications for diabetes, diagnosis of hemophilia,
cancer with chemotherapy 4 weeks before the examination,
or pregnancy. The eligible participants were instructed to fast
for 10 to 16 hours before the morning blood draw. The
specimen was obtained at the time of the initial venipuncture
and processed using standard radioimmunoassay methods by
highly trained medical personnel who had completed com-
prehensive training in standardized laboratory procedures.
Equipment operation, specimen collection and preparation,
and testing procedures were monitored for quality assurance
with detailed instructions in the manual of medical techni-
cians (US Department of Health and Human Services,
1996).17,18 The minimal reportable range for C-peptide levels
was 0.021 nmol/L; values below the detection limit were
coded in this study as 0.021. The coefﬁcient of variation for
the lower extreme of the values was 14.7% (for mean
C-peptide levels of 0.265, 95% conﬁdence interval [CI] 0.187
to 0.343 nmol/L) and 6.6% for the upper extreme of the
values (for mean C-peptide levels of 3.311, 95% CI 2.875 to
3.747 nmol/L).18
Covariates that were studied at baseline for potential
confounding assessment included standard demographics
such as age, sex, ethnicity (white, black, Mexican, and other)
and education level (less than, equivalent to, and above high
school). Based on previous literature, we also assessed the
following variables that are known to relate to the develop-
ment of diabetes or cardiovascular disease: alcohol use (>1
for female and >2 for male, ≤1 for female and ≤2 for male,
and 0, drinks in the last month),19 physical activity (none, <3,
and ≥3, times per week),20 fasting plasma glucose levels,21
glycated hemoglobin (A1c) levels,22 body mass index,20
estimated glomerular ﬁltration rate by Modiﬁcation of Diet
in Renal Disease (MDRD) formula23 (≥90, 60 to 89, and
<60 mL/min),24 urinary albumin/creatinine ratio,25 and
C-reactive protein levels.26,27 Also included were cardiovascular
risk factors from the Third Adult Treatment Panel (ATP 3)
guidelines5 such as smoking status (current, former, and
never), blood pressure (<130/80, 130 to 139 systolic or 80 to
89 diastolic, and ≥140 systolic or 90 diastolic, mm Hg), total
cholesterol, high-density lipoprotein (HDL) cholesterol, and
calculated low-density lipoprotein (LDL) cholesterol (total
cholesterol[triglycerides/5]HDL)28; components of meta-
bolic syndrome not already included from the same guidelines
(triglycerides, waist-to-hip ratio),5 family history of heart
attack or diabetes, as well as a personal history of stroke,
heart attack, chest pain (none, suggestive, and not suggestive,
of angina), and peripheral arterial disease.
Statistical Analysis
Given the complex nonrandom multistage stratiﬁed sample
design of NHANES 3, analyses were performed using the
designated weighting speciﬁed in the data set to minimize
biases.29 As such, we used the total NHANES 3 pseudostratum
as our strata variable, the total pseudoprimary sampling units
as our survey sampling units, and the total mobile examination
center (MEC) ﬁnal weight as our sampling unit weight.
First, we evaluated the sensitivity and speciﬁcity of several
indices of insulin resistance in the prediction of cardiovascular
and overall death by means of receiver operating characteristic
(ROC) curves and evaluated their correlation with C-peptide
levels. The indices included fasting levels of serum C-peptide,
serum insulin,6 and plasma glucose, as well as the homeostatic
model assessment of insulin resistance (HOMA-IR index),30
quantitative insulin sensitivity check index (QUICKI index),31
and metabolic syndrome.5 Next, we identiﬁed the index of
insulin resistance with the largest ROC area under the curve
(AUC) and used it as the reference for comparison against the
AUC of other indices using chi-square analysis. The ROC
analyses were frequency weighted using NHANES 3 probability
weights rounded to the nearest integer.32
We then stratiﬁed our study sample by quartiles of
C-peptide levels (≤0.418, 0.419 to 0.652, 0.653 to 0.983,
and ≥0.984 nmol/L). Differences in baseline characteristics
among subjects across C-peptide quartiles were compared
using linear regression for continuous variables and v2
analysis for categorical variables. Kaplan–Meier curves were
created to estimate the percent of event-free period of
survival according to C-peptide quartiles. The association
between C-peptide quartiles and study outcomes over time
was examined using Cox proportional-hazards modeling with
subjects in the lowest C-peptide quartile (≤0.418 nmol/L) as
the reference category. We adjusted for potential confounding
in a model that included all the assessed covariates with the
exception of LDL cholesterol due to its high collinearity with
other lipid variables. The resulting model yielded excellent
discrimination with a Harrell’s C statistic of 0.82 for
cardiovascular mortality and 0.78 for overall mortality. We
tested for assumption of proportional hazards on the primary
outcome by visual inspection of the Kaplan–Meier curves as
well as the inclusion of an interaction term of C-peptide
quartiles with log(time) in the Cox model.33 The comparison of
the Cox models with and without the interaction term showed
no signiﬁcant difference by likelihood-ratio test (P=0.94),
conﬁrming the assumption of the proportional hazards. We
also estimated the attributable risk percent for the cardio-
vascular and overall death in relationship to C-peptide levels
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to determine the excess risk associated with high C-peptide
levels,34 where the “exposed” group was deﬁned by the top
quartile of C-peptide levels and the “unexposed” group by the
remaining population.
Additional analyses on the primary outcome were
performed to test whether potential interaction between
C-peptide levels and body mass index, sex, race, or glomerular
ﬁltration rate (≥60 mL/min vs <60 mL/min) existed. In
addition, subgroup analyses were performed for individuals
with normal fasting glucose (<100 mg/dL) and in those
without metabolic syndrome as deﬁned by the ATP 3 criteria,5
and in speciﬁc outcomes of interest; namely, death due to
cerebrovascular disease, ischemic heart disease, and myo-
cardial infarction (included in the ischemic heart disease
death). To identify whether the association with mortality
differed for C-peptide compared with other biochemical
markers of insulin resistance (HOMA-IR, QUICKI, and serum
insulin levels), we also studied the effect of using these other
biochemical markers in lieu of C-peptide quartiles in the
survival models.
Data was 98.6% complete for all covariates, with missing
values that ranged from 0.1% (history of peripheral arterial
disease) to 2.5% (waist-to-hip ratio). Missing data in the
covariates were imputed based on 10 sets of simulated values
generated from nonmissing variables using the multiple
imputation method in STATA (StataCorp, College Station,
Tex).35 Analyses were performed on each of the 10 data sets
completed with imputed values, and then combined using
Rubin’s combination rules to consolidate the individual
estimates into a single set of estimates using the MI estimate
command in STATA.36,37 All statistical analyses were con-
ducted in STATA SE 11.1.38 A 2-sided P value of <0.05 was
considered signiﬁcant.
Results
Baseline Characteristics of the Study Population
Our ﬁnal analytic sample included 5153 nondiabetic adults
between 40 and 74 years of age, which was representative of
a population of 61 651 227 nondiabetic US adults of the
same age group. The baseline clinical characteristics of the
study population, both overall and according to C-peptide
category, are shown in Table 2. Increasing quartiles of
C-peptide levels were associated with higher likelihoods of
having an older age, male gender, nonwhite ethnicity,
education less than high school, previous or current smoking
history, personal history of heart attack, chest pain or stroke;
family history of diabetes, blood pressure ≥140/90, and
metabolic syndrome. Compared with participants in the
lowest C-peptide quartile, participants in the higher C-peptide
quartiles were also more likely to have a higher waist-to-hip
ratio and body mass index. Participants in the lowest C-
peptide quartile, on the other hand, were more likely to have
exercised ≥3 times a week, to have consumed alcohol in the
month before the survey, and to have a blood pressure <130/
80 compared with participants in higher C-peptide quartiles
(Table 2).
The baseline biochemical characteristics of the study
population, both overall and according to C-peptide category,
are shown in Table 3. Compared with participants in the
lowest C-peptide quartile, participants in the higher C-peptide
quartiles were more likely to have higher plasma glucose
during fasting and 2-hour post-glucose tolerance test, urinary
albumin/creatinine ratio, A1c, total and LDL cholesterol,
triglyceride, serum fasting insulin, and C-reactive protein
levels, as well as the HOMA-IR index. On the other hand,
participants in the lowest C-peptide quartile were more likely
to have a higher HDL cholesterol level, QUICKI index, and
glomerular ﬁltration rate ≥90 mL/min than were participants
in the higher C-peptide quartiles.
Comparison of C-Peptide With Other Indices of
Insulin Resistance
C-peptide levels had a high correlation (P<0.001) with other
biochemical indices of insulin resistance such as HOMA-IR
(r=0.78), QUICKI (r=0.78), and serum insulin levels (r=0.77).
ROC curve analyses showed that fasting serum C-peptide
levels had the largest AUC in the prediction of subsequent
cardiovascular, and overall death compared with other indices
of insulin resistance (Table 4). C-peptide levels (AUC=0.62)
had signiﬁcantly higher AUC’s compared with fasting plasma
glucose levels (AUC=0.56), HOMA-IR index (AUC=0.58),
fasting serum insulin levels (AUC=0.57), QUICKI index
(AUC=0.42), and metabolic syndrome (AUC=0.56) for cardio-
vascular death, with P values at <0.001. A similar pattern was
found for overall mortality (AUC=0.60 for C-peptide levels vs
AUC=0.57 or less in the rest).
C-Peptide Levels and Mortality
The median follow-up for the study was 14.4 years (inter-
quartile range: 3.3 years), with a total follow-up of 70 768
person-years. A total of 513 deaths occurred during the
follow-up period. Crude cumulative mortality rates increased
signiﬁcantly with increasing quartiles of C-peptide levels for
cardiovascular death (Figure 1), cerebrovascular disease
death, ischemic heart disease death, myocardial infarction
death, and overall mortality (P values <0.01 for all, Table 5).
Of note, cardiovascular mortality was only one-third of the
overall mortality at the lowest C-peptide quartile, but they
were approximately half of the overall mortality for individ-
uals at the highest C-peptide quartile. The association
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Table 2. Baseline Clinical Characteristics of the Study Population, According to Fasting C-Peptide Levels
C-Peptide Category, nmol/L
Overall ≤0.418 0.419 to 0.652 0.653 to 0.983 ≥0.984 P Value
No. of participants 5153 1288 1288 1290 1287 <0.01
Mean ageSD, y 54.910.5 53.410.2 55.010.5 55.110.4 56.110.7
Sex, % <0.01
Male 48.3 42.1 46.1 50.7 56.2
Female 51.7 57.9 53.9 49.3 43.8
Ethnicity, % 0.01
White 81.7 83.3 80.8 82.6 80
Black 8.4 8.7 8.7 8.2 7.7
Mexican 3.2 2.1 2.8 3.7 4.6
Others 6.7 5.9 7.7 5.5 7.7
Education, % <0.01
Less than high school 23.6 18.9 23.2 25.7 27.5
High school or equivalent 33.5 32.5 30.7 35.5 36
College or above 42.4 48.1 45.6 38.3 36.1
Smoking status, %* <0.01
Current 25.7 25.6 27.3 24.5 25.1
Former 33.7 31.2 28.6 36.2 40.3
Never 40.6 43.2 44.1 39.3 34.6
History of stroke, % 1.7 1.2 1.4 2.1 2.1 0.58
History of heart attack, % 4.0 2.4 2.7 4.3 7.1 <0.01
History of chest pain, % <0.01
Suggestive of angina 4.7 3.3 3.8 5.3 7.0
Not suggestive of angina 28.7 26.6 25.1 30.7 33.2
No chest pain 66.6 70.1 71.1 64 59.8
Peripheral arterial disease, % 0.9 0.2 1.3 0.3 2.3 <0.01
Family history of heart attack, % 10.7 10.1 10.9 11.4 10.6 0.51
Family history of diabetes, % 25.3 22.1 24.3 24.9 31.1 0.02
Blood pressure, % <0.01
<130/80, mm Hg 51.3 66.0 53.9 46.2 35.3
130 to 139/80 to 89, mm Hg 26.1 19.2 27.4 30.4 28.6
≥140/90, mm Hg 22.5 14.8 18.4 23.3 36.0
Alcohol use, % <0.01
0 drink/last month 46.1 41.2 42.8 48.9 53.2
≤2 drinks/day if male and ≤1 drink/day if female 49.5 52.8 52.7 47.6 43.4
>2 drinks/day if male and >1 drink/day if female 4.3 5.8 4.4 3.4 3.3
Physical activity, % <0.01
No activity 13.8 11.4 11.3 15.7 17.4
<3 times/week 31.1 23.6 33.7 33.9 34.5
Mean waist-to-hip ratioSD 0.90.1 0.90.1 0.90.1 1.00.1 1.00.1 <0.01
Mean body mass indexSD, kg/m2 27.55.5 23.93.7 26.34.3 28.64.9 31.25.9 <0.01
Metabolic syndrome, %† 24.5 3.4 12.1 32.3 57.4 <0.01
Frequencies (%) in the columns may not sum to 100% to account for missing data.
*Participants were classiﬁed into current smoker if he or she had smoked at least 100 cigarettes during his or her entire life and still smokes, former smoker if he or she had smoked at
least 100 cigarettes during his or her entire life but not currently smoking; and never if he or she had never smoked >100 cigarettes during his or her entire life.
†Metabolic syndrome is diagnosed when ≥3 of the following criteria are present; waist circumference >102 cm for men and >88 cm for women, triglycerides level >150 mg/dL, high-
density lipoprotein level <40 mg/dL for men and <50 mg/dL for women, blood pressure ≥130/≥85 mm Hg, and fasting glucose ≥110 mg/dL. (Ref Third report of the National
Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults)
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between C-peptide quartiles and mortality persisted even
after adjustment for potential confounding factors (Table 5).
When compared with individuals in the lowest quartile of
C-peptide levels (≤0.418 nmol/L), subjects in the highest
C-peptide quartile (≥0.984 nmol/L) had a 60% increase in
the adjusted hazards of cardiovascular death. A similar
pattern and magnitude of increased hazards of mortality for
individuals in the highest C-peptide quartile were found for
cerebrovascular disease, ischemic heart disease, myocardial
infarction, and overall mortality compared with participants
in the lowest quartile of C-peptide levels. Of note, analyses
of speciﬁc outcomes such as death due to ischemic heart
disease and myocardial infarction did not reach statistical
signiﬁcance, except for cerebrovascular disease death
(adjusted HR=3.94, 95% conﬁdence interval [CI] 1.28 to
12.1), although their 95% CIs of these speciﬁc outcomes
overlap with those of cardiovascular and overall mortality
(Table 5). The attributable risk percent for individuals with
C-peptide levels in the highest quartile vs the remaining of
the population was 52% for cardiovascular mortality and
40.6% for overall mortality.
Although additional analyses did not show a signiﬁcant
interaction between body mass index, sex, or race, and
C-peptide levels, we did ﬁnd an interaction of borderline
signiﬁcance (P=0.04) between kidney function and the highest
quartile of C-peptide levels. Indeed, for subjects with a
glomerular ﬁltration rate <60 mL/min, the adjusted HR of
cardiovascular death were 3.73 (95% CI 1.18 to 11.7) for
individuals in the highest vs the lowest quartiles of C-peptide
levels. On the other hand, for subjects with a glomerular
ﬁltration rate ≥60 mL/min, the adjusted HR of cardiovascular
death were nonsigniﬁcantly elevated at 1.34 (0.82 to 2.19) for
individuals in the highest vs the lowest quartiles of C-peptide
levels. Subgroup analyses on individuals with a normal fasting
glucose and in those without metabolic syndrome showed
consistency of C-peptide quartiles as an independent predic-
tor of cardiovascular death (Table 6).
From the Cox model, independent clinical predictors
associated with higher hazards of cardiovascular death were
increasing age, male, blood pressure ≥140 mm Hg systolic or
90 mm Hg diastolic, education less than high school vs
college level, current smoking, previous stroke, previous heart
Table 3. Baseline Biochemical Characteristics of the Study Population, According to Fasting C-Peptide Levels
C-Peptide Category, nmol/L
Overall ≤0.418 0.419 to 0.652 0.653 to 0.983 ≥0.984 P Value
No. of participants 5153 1288 1288 1290 1287 <0.01
Mean hemoglobin A1cSD, % 5.40.5 5.30.4 5.40.4 5.40.5 5.50.5
Glomerular ﬁltration rate, %* <0.01
≥90, mL/min 4.3 4.6 4.2 4.8 3.5
60 to 89, mL/min 70.3 76.7 71.7 69.8 61.2
<60, mL/min 24.2 17.4 23.3 23.8 34.2
Mean fasting plasma glucoseSD, mg/dL 95.59.2 90.97.5 94.88.2 96.88.8 99.59.8 <0.01
Mean 2 h OGTTSD, mg/dL 121.234 115.634.8 117.232.9 124.433.4 127.233.3 <0.01
Mean serum cholesterolSD, mg/dL 220.643.1 213.941.9 221.340.4 222.244.8 224.944.3 <0.01
Mean serum HDLSD, mg/dL 51.516.2 59.617.5 53.415.9 48.413.9 44.713.2 <0.01
Mean serum triglyceridesSD, mg/dL 149.4106.2 105.669.7 128.876.8 161.4106.2 201.9133.8 <0.01
Mean calculated serum LDLD, mg/dL† 140.438.7 133.938.3 142.837.7 142.539.5 142.638.8 <0.01
Mean serum insulinSD, pmol/L 65.247.3 34.412.7 47.613.4 64.719.1 114.267.8 <0.01
Mean serum CRPSD, mg/dL‡ 0.50.7 0.40.6 0.40.7 0.50.8 0.60.7 <0.01
Mean urinary albumin/creatinineratioSD, mg/g 21.2110.9 10.334.8 16.594.2 23.3127.3 34.8150.6 <0.01
Mean HOMA§ 15.612.5 7.83.0 11.23.4 15.54.8 28.218.5 <0.01
Mean QUICKI|| 0.270.02 0.290.01 0.280.01 0.270.01 0.250.01 <0.01
Frequencies (%) in the columns may not sum to 100% to account for missing data.
OGTT indicates oral glucose tolerance test; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein; HOMA, homeostatic model assessment; QUICKI,
quantitative insulin sensitivity check index.
*MDRD formula was used to calculate GFR. GFR=186*serum creatinine1.154age0.2031.210 (for black)0.742 (for female). GFR is in mL/min/1.73 m2 body surface area.
†LDL was calculated using following formula: LDL=total cholesterolHDL0.20serum triglycerides if triglycerides ≤400 mg/dL. For triglycerides >400 mg/dL, LDL value was considered
missing.
‡Lowest detection limit for biochemistry test used in NHANES 3 for C-reactive protein was 0.3 mg/dL.
§HOMA=fasting plasma glucose (mg/dL)9fasting serum insulin levels/405.
||QUICK index=1/(log [fasting serum insulin]+log [fasting plasma glucose]).
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attack, and peripheral arterial disease. Independent biochem-
ical predictors of cardiovascular and/or diabetes death
included C-reactive protein levels, urinary albumin/creatinine
ratio, and C-peptide levels (Table 7). Neither A1c, body mass
index, nor fasting plasma glucose levels was an independent
predictor of cardiovascular death in the model.
When other biochemical indices of insulin resistance such as
serum insulin levels, HOMA-IR, and QUICKI were used in lieu of
quartiles C-peptide levels in the study survival models, we only
found a signiﬁcant association between these other biomarkers
andoverallmortalitybutnotwithcardiovascularmortality (Table 8).
Discussion
Very few studies, if any, evaluated the role of fasting serum
C-peptide as a biomarker for future cardiovascular death. The
present study suggests that fasting serum C-peptide levels
were a better predictor of cardiovascular and overall death
than fasting serum insulin and its derived measures of insulin
resistance in a nationwide sample of nondiabetic adults
between 40 and 74 years of age. The effects were indepen-
dent of several known risk factors for development of
diabetes or cardiovascular disease and were consistent even
in patients without metabolic syndrome or with normoglyce-
mia. The increased risk of cardiovascular or overall death was
60% and 72% higher, respectively, for participants in the
highest vs lowest C-peptide quartiles, with consistent patterns
observed in subgroup analyses for mortality due to cerebro-
vascular disease, ischemic heart disease, or myocardial
infarction.
Substantial evidence supports the role of insulin resistance
in the development of type 2 diabetes,7,39 but a relationship
between insulin resistance-hyperinsulinemia as measured by
C-peptide levels in adults without diabetes and a future
cardiovascular death has not been established from our
literature review. This association remained signiﬁcant for
adults without clinical manifestations of insulin resistance
such as those with normal fasting glucose levels or without
metabolic syndrome at the time of C-peptide level testing.
Thus, these results support the role of C-peptide levels to be
an important predictor of mortality. Studies in women with
breast cancer have also used C-peptide levels as an important
prognostic indicator.11,40 Irwin et al11 use C-peptide to track
the metabolic proﬁle of patients with breast cancer, because
both glucose and lipid dysregulation have been associated
with incidence of breast cancer.41,42 The authors found an
increased risk of overall and breast cancer mortality associ-
ated with higher C-peptide levels in the population of
Table 4. Receiver Operating Characteristic Curves of
Different Indices of Insulin Resistance to Predict
Cardiovascular or Overall Death
Indices of Insulin Resistance
Area Under the Curve
(95% Conﬁdence Interval)
P Value vs
C-Peptide
Cardiovascular death
Fasting serum C-peptide
levels, nmol/L
0.624 (0.624 to 0.625) —
Fasting plasma glucose
levels, mg/dL
0.558 (0.558 to 0.558) <0.001
HOMA-IR index 0.583 (0.583 to 0.583) <0.001
Fasting serum insulin
levels, pmol/L
0.567 (0.566 to 0.567) <0.001
QUICKI index 0.417 (0.417 to 0.418) <0.001
Metabolic syndrome 0.563 (0.563 to 0.563) <0.001
Overall mortality
Fasting serum C-peptide
levels, nmol/L
0.600 (0.600 to 0.600) —
Fasting plasma glucose
levels, mg/dL
0.566 (0.566 to 0.566) <0.001
HOMA-IR index 0.559 (0.558 to 0.559) <0.001
Fasting serum insulin
levels, pmol/L
0.549 (0.549 to 0.549) <0.001
QUICKI index 0.442 (0.441 to 0.442) <0.001
Metabolic syndrome 0.543 (0.543 to 0.543) <0.001
Analysis was frequency weighted using NHANES 3 probability weights rounded to the
nearest integer. Some 95% conﬁdence intervals are extremely narrow or showed no
variation due to rounding to the nearest 3 decimal points.
HOMA-IR indicates homeostatic model assessment of insulin resistance; QUICKI,
quantitative insulin sensitivity check index.
HOMA=fasting plasma glucose (mg/dL)9fasting serum insulin levels/405.
QUICKI index=1/(log [fasting serum insulin]+log [fasting plasma glucose]).
Metabolic syndrome by ATP3 criteria is diagnosed when ≥3 of the following criteria are
present: waist circumference >102 cm for men and >88 cm for women, triglycerides
level >150 mg/dL, high-density lipoprotein level <40 mg/dL for men and <50 mg/dL
for women, blood pressure ≥130/≥85 mm Hg, and fasting glucose ≥110 mg/dL.
Log rank P <0.01
Figure 1. Kaplan–Meier Curve and percent survival estimates for
cardiovascular disease death according to quartiles of C-peptide
levels. Quartile 1=0.418 nmol/L or less, Quartile 2=0.419 to
0.652 nmol/L, Quartile 3=0.653 to 0.983 nmol/L, Quartile
4=0.984 nmol/L or greater.
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nondiabetic women with breast cancer.11 Our study builds on
these results by showing that the increased mortality risk
associated with high C-peptide levels applied to both men and
women of the general population between 40 and 74 years of
age. Other indices of insulin resistance such as HOMA-IR, that
uses a product of serum insulin and plasma glucose levels,
have also been shown to be an adverse prognostic indicator
for cardiovascular and overall mortality.10 However, the utility
of direct serum insulin measurements is limited by its short
half-life.12–14 In addition to supporting the increased mortality
risk associated with an insulin resistant state with C-peptide
levels, we found C-peptide levels to be a better predictor of
cardiovascular and overall mortality compared with serum
insulin levels. Indeed, C-peptide levels outperformed other
known markers of insulin resistance such as HOMA-IR,
QUICKI, and metabolic syndrome, among others, in the risk
prediction models of cardiovascular and overall death. When
compared with other independent predictors of cardiovascu-
lar death found in our study, the increased hazards associated
with the highest vs the lowest C-peptide quartile were
comparable to that of being of male gender or a current
smoker or to have elevated C-reactive protein levels. Our
ﬁndings suggest that the attributable risk of cardiovascular
death associated with C-peptide levels in the upper quartile of
the population is 52%.
The association between high C-peptide levels and
increased risk of cardiovascular death likely reﬂects the
association between insulin resistance and an atherogenic
state.43 This hypothesis is supported by the majority of
deaths associated with high C-peptide levels being attributed
to macrovascular disease (cerebrovascular and ischemic heart
disease, and myocardial infarction) death. Although the
results might appear that the point estimate for cerebrovas-
cular disease death was higher than the ischemic heart
disease or myocardial infarction death, the event rates were
low and the 95% CIs overlap to avoid such conclusions. Future
Table 5. HRs for Mortality Outcomes During the Study Period, According to Quartiles of C-Peptide Levels
C-Peptide Category, nmol/L
Overall ≤0.418 0.419 to 0.652 0.653 to 0.983 ≥0.984
No. of participants 5140 1284 1283 1290 1283
Cardiovascular mortality, %* 7.2 3.8 6.0 7.9 12.2
Crude HR for cardiovascular mortality (95% CI) Referent 1.61 (1.13 to 2.33) 2.18 (1.40 to 3.28) 3.44 (2.38 to 5.03)
Adjusted HR for cardiovascular mortality (95% CI) Referent 1.20 (0.80 to 1.80) 1.42 (0.90 to 2.26) 1.60 (1.07 to 2.39)
No. of participants 5140 1284 1283 1290 1283
Cerebrovascular disease mortality, %* 1.0 0.5 0.6 0.8 2.2
Crude HR for cerebrovascular disease mortality (95% CI) Referent 1.33 (0.53 to 3.37) 1.83 (0.60 to 5.57) 4.82 (1.81 to 12.8)
Adjusted HR for cerebrovascular disease mortality (95% CI) Referent 1.12 (0.44 to 2.83) 1.22 (0.28 to 5.34) 3.94 (1.28 to 12.1)
No. of participants 5140 1284 1283 1290 1283
Ischemic heart disease mortality, %* 3.9 2.1 3.5 4.2 6.3
Crude HR for ischemic heart disease mortality (95% CI) Referent 1.67 (1.04 to 2.69) 2.05 (1.30 to 3.26) 3.15 (2.07 to 4.81)
Adjusted HR for ischemic heart disease mortality (95% CI) Referent 1.17 (0.66 to 2.10) 1.16 (0.65 to 2.06) 1.22 (0.67 to 2.21)
No. of participants 5140 1284 1283 1290 1283
Myocardial infarction mortality, %* 1.5 1.0 1.3 1.1 2.9
Crude HR for myocardial infarction mortality (95% CI) Referent 1.22 (0.59 to 2.51) 1.13 (0.44 to 2.92) 3.00 (1.32 to 6.79)
Adjusted HR for myocardial infarction mortality (95% CI) Referent 0.79 (0.37 to 1.67) 0.71 (0.25 to 2.01) 1.37 (0.66 to 2.83)
No. of participants 5152 1288 1287 1290 1287
Overall mortality, %* 18.1 12.3 14.7 20.6 26.4
Crude HR for overall mortality (95% CI) Referent 1.22 (0.94 to 1.57) 1.77 (1.42 to 2.18) 2.31 (1.77 to 2.99)
Adjusted HR for overall mortality (95% CI) Referent 1.12 (0.88 to 1.43) 1.57 (1.27 to 1.95) 1.72 (1.34 to 2.21)
ICD-10 codes were used to deﬁne underlying cause of death. Cardiovascular mortality was deﬁned as cardiovascular disease (I00 to I99) being the underlying cause of death or when it was
one of the multiple causes of the death (American Heart Association 2011 update on heart disease and stroke).16 Cerebrovascular disease, ischemic heart disease, and myocardial
infarction deaths are part of the cardiovascular disease death. Myocardial infarction death is part of the ischemic heart disease death.
Model was adjusted for age, sex, race, waist-to-hip ratio, body mass index, blood pressure, total cholesterol, triglycerides, high-density lipoprotein, history of stroke, heart attack, peripheral
arterial disease, family history of diabetes and heart attack, history of chest pain, level of education, smoking status, level of physical activity, alcohol use in last month, C-reactive protein
level, urinary albumin/creatinine ratio, glomerular ﬁltration rate, and glycated hemoglobin levels. Bold values represent statistically signiﬁcant results at P values of <0.05.
*P value <0.01 among quartiles. Mortality rates are population-weighted averages calculated based on NHANES 3 probability weights rounded to the nearest integer.
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studies will be needed to further investigate the relationship
between C-peptide levels and speciﬁc macrovascular disease
states. Other explanations for the increased risk of death
associated with high C-peptide levels despite adjustment for
known cardiovascular risk factors may be that high C-peptide
levels predict the future worsening of the current risk factors
and/or the future development of diabetes or cardiovascular
disease.7,8 Another possibility is the existence of other
signiﬁcant predictors of cardiovascular death that we did
not account for in our Cox model, such as diastolic
dysfunction,44 endothelial dysfunction,45 and prothrombotic
states.46,47
In addition, we found a weak but signiﬁcant interaction
between kidney function and high C-peptide levels, where the
cardiovascular mortality risk associated with high C-peptide
levels was signiﬁcantly more accentuated among individuals
with glomerular ﬁltration rates <60 mL/min. Potential mech-
anisms for this interaction could be the increased endothelial
dysfunction, inﬂammation and oxidative stress, among other
cardiovascular risk factors that coexist in individuals with
kidney disease,48–50 in addition to the excess cardiovascular
risk associated with insulin resistance. On the other hand, our
results did not show a signiﬁcant interaction between
C-peptide levels and body mass index, which is in contrast
with the report by Ausk et al,10 who found HOMA-IR a
signiﬁcant predictor of overall mortality but only in individuals
with a normal body mass index. While this discrepancy may
be partly explained by the older age of our study population
(40 to 74 years vs ≥20 years in the Ausk et al report), it is
also possible that fasting serum C-peptide level is a more
stable measure of insulin secretion and, therefore, produced
more robust results across different stages of obesity than
HOMA-IR.9,13,14
The results of this study should be interpreted in the
context of several limitations. First, despite the signiﬁcant
relationship between C-peptide levels and mortality, the power
of discrimination of C-peptide levels on the cardiovascular and
overall mortality is only modest with AUCs of 0.62 and 0.60,
respectively. Nevertheless, the ROC for C-peptide was signif-
icantly better than all other indices of insulin resistance for the
outcomes studied. Second, although we had data on deaths
and the causes of death, we could not evaluate data on
nonfatal cardiovascular events, which could have increased
the power to detect smaller differences between exposure
groups and shed light on the potential new mechanisms of
harm from insulin resistance. Third, given the observational
nature of our study, the possibility of residual confounding
exists. Despite our efforts using both multivariate adjustment
Table 7. Multivariate Adjusted HRs of Independent Covariate
Predictors of Cardiovascular Death
Independent Predictors Adjusted HRs (95% CI)
Age, y 1.10 (1.08 to 1.12)
Male 1.65 (1.23 to 2.21)
Blood pressure ≥140 mm Hg
systolic or 90 mm Hg diastolic
2.00 (1.45 to 2.77)
Education less than high
school versus college level
1.42 (1.04 to 1.95)
Current smoking 1.96 (1.33 to 2.88)
Previous stroke 2.32 (1.45 to 3.71)
Previous heart attack 2.51 (1.67 to 3.76)
Peripheral arterial disease 2.73 (1.32 to 5.64
C reactive protein levels, mg/dL 1.21 (1.03 to 1.42)
Urinary albumin/creatinine ratio 1.001 (1.001 to 1.001)
Model was adjusted for age, sex, race, waist-to-hip ratio, body mass index, blood
pressure, total cholesterol, triglycerides, high-density lipoprotein, history of stroke, heart
attack, peripheral arterial disease, family history of diabetes or heart attack, history of
chest pain, level of education, smoking status, level of physical activity, alcohol use in
last month, C-reactive protein level, urinary albumin/creatinine ratio, glomerular ﬁltration
rate, and glycated hemoglobin levels.
Table 6. Adjusted Hazard Ratio for Cardiovascular Death in Subgroups, According to Quartiles of C-Peptide Levels
Adjusted Hazard Ratios According Quartiles of C-Peptide Levels, nmol/L (95% CI)
≤0.418 0.419 to 0.652 0.653 to 0.983 ≥0.984
No metabolic syndrome* (n=3784) Referent 1.32 (0.84 to 2.08) 1.72 (1.10 to 2.69) 2.01 (1.29 to 3.11)
Plasma glucose levels <100 mg/dL (n=3703) Referent 1.20 (0.77 to 1.87) 1.34 (0.68 to 2.64) 1.74 (1.02 to 2.95)
Glomerular ﬁltration rate ≥60 mL/min (n=3952)† Referent 1.10 (0.68 to 1.80) 1.35 (0.84 to 2.16) 1.34 (0.82 to 2.19)
Glomerular ﬁltration rate <60 mL/min (n=1115)† Referent 2.63 (0.86 to 8.02) 3.03 (0.94 to 9.83) 3.73 (1.18 to 11.7)
Model was adjusted for age, sex, race, waist-to-hip ratio, body mass index, blood pressure (normal, prehypertension, hypertension), total cholesterol, triglycerides, high-density lipoprotein,
presence or absence of past history of stroke, heart attack, peripheral arterial disease, presence or absence of family history of diabetes and heart attack, history of chest pain (suggestive
of angina, not suggestive of angina and no chest pain), level of education, smoking status, level of physical activity (no physical activity in last month, physical activity levels, alcohol use,
C-reactive protein level, urinary albumin/creatinine ratio, glomerular ﬁltration rate, and glycated hemoglobin levels. Bold values represent statistically signiﬁcant results at P values of <0.05.
*Metabolic syndrome is diagnosed based on ATP3 criteria, when ≥3 of the following criteria are present; waist circumference >102 cm for men and >88 cm for women, triglycerides level
>150 mg/dL, high-density lipoprotein level <40 mg/dL for men and <50 mg/dL for women, blood pressure ≥130/≥85 mm Hg, and fasting glucose ≥110 mg/dL (Third report of the
National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults).5
†Interaction glomerular ﬁltration ratefourth quartile of C-peptide level was signiﬁcant at a P value <0.04.
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for several demographic and clinical known confounders for
cardiovascular disease and diabetes, and stratiﬁed analyses to
control for the inﬂuence of potential confounding, the
possibility for “residual confounding” in our statistical model-
ing may still exist and should be taken into account in the
interpretation of our results. Fourth, the use of death
certiﬁcates to adjudicate causes of death may lead to potential
misclassiﬁcation.51–53 Despite this limitation, the accuracy of
death certiﬁcates is higher for deaths related to diseases of
the circulatory system, with a sensitivity of 82% and a positive
predictive value of 75%.53 Finally, repetitive measurements of
the different biological measures were not available. Ideally,
the analysis of the cardiovascular death outcome should be
repeated after exclusion of individuals who developed diabetes
during follow-up, which is one of the potential mechanisms at
which insulin resistance could lead to cardiovascular death.
Therefore, the current study could not discern whether the
increased cardiovascular death risk in individuals with
insulin resistance was due to the insulin resistance status
per se or due to future development of risk factors such as
diabetes. However, our analyses adjusted for several known
risk factors for development of diabetes and subgroup
analyses in individuals with lower risk of future diabetes,
such as those without metabolic syndrome and those with
normal fasting plasma glucose levels, consistently showed
increased cardiovascular death risk among study partici-
pants in the highest quartile of C-peptide levels. These
results would support that the increased risk of cardiovas-
cular death in subjects with high C-peptide levels is unlikely
to be attributed solely to the eventual development of
diabetes, and suggest additional or alternative mechanisms
of harm.
In summary, C-peptide was superior to other insulin-
derived measures of insulin resistance in predicting cardio-
vascular and overall death in nondiabetic adults. C-peptide
predicted cardiovascular death even in subjects with normo-
glycemia and without metabolic syndrome. Prospective stud-
ies are needed to elucidate the usefulness of C-peptide levels
as a target for intervention to improve cardiovascular
outcomes.
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Table 8. HRs for Mortality Outcomes During the Study Period, According to Other Biochemical Indices of Insulin Resistance
(N=5152)
Fasting Insulin Levels, pmol/L HOMA-IR QUICKI
Adjusted HR for cardiovascular mortality (95% CI)
Quartile 1 Referent Referent Referent
Quartile 2 0.85 (0.59 to 1.21) 0.93 (0.61 to 1.42) 1.00 (0.71 to 1.40)
Quartile 3 1.10 (0.70 to 1.71) 1.13 (0.73 to 1.74) 0.82 (0.57 to 1.18)
Quartile 4 1.08 (0.66 to 1.77) 1.13 (0.72 to 1.78) 0.88 (0.56 to 1.38)
Adjusted HR for overall mortality (95% CI)
Quartile 1 Referent Referent Referent
Quartile 2 0.95 (0.81 to 1.12) 1.00 (0.83 to 1.20) 0.95 (0.78 to 1.15)
Quartile 3 1.29 (0.98 to 1.71) 1.29 (1.02 to 1.64) 0.74 (0.56 to 0.97)
Quartile 4 1.35 (1.00 to 1.81) 1.36 (1.01 to 1.82) 0.74 (0.55 to 0.99)
CI indicates conﬁdence interval; HR, hazard ratio; HOMA-IR, fasting plasma glucose (mg/dL)9fasting serum insulin levels/405; QUICKI index, 1/[log (fasting serum insulin)+log (fasting
plasma glucose)].
Model was adjusted for age, sex, race, waist-to-hip ratio, body mass index, blood pressure, total cholesterol, triglycerides, high density lipoprotein, history of stroke, heart attack, peripheral
arterial disease, family history of diabetes and heart attack, history of chest pain, level of education, smoking status, level of physical activity, alcohol use in last month, C-reactive protein
level, urinary albumin/creatinine ratio, glomerular ﬁltration rate, and glycated hemoglobin levels. Bold values represent statistically signiﬁcant results at P values of <0.05.
DOI: 10.1161/JAHA.112.003152 Journal of the American Heart Association 10
C-Peptide and CVD Death Patel et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2018
Disclosures
None.
References
1. DeFronzo R, Ferrannini E. Insulin resistance: a multifaceted syndrome
responsible for NIDDM, obesity, hypertension, dyslipidemia, and atheroscle-
rotic cardiovascular disease. Diabetes Care. 1991;14:173–194.
2. Ades PA, Savage PD, Toth MJ, Schneider DJ, Audelin MC, Bunn JY, Ludlow M.
The inﬂuence of obesity and consequent insulin resistance on coronary risk
factors in medically treated patients with coronary disease. Int J Obes (Lond).
2008;32:967–974.
3. Pihlajamaki J, Gylling H, Miettinen TA, Laakso M. Insulin resistance is
associated with increased cholesterol synthesis and decreased cholesterol
absorption in normoglycemic men. J Lipid Res. 2004;45:507–512.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet.
2005;365:1415–1428.
5. Third Report of the National Cholesterol Education Program (NCEP). Expert
panel on detection, evaluation, and treatment of high blood cholesterol
in adults (Adult Treatment Panel III) ﬁnal report. Circulation. 2002;106:
3143.
6. Laakso M. How good a marker is insulin level for insulin resistance? Am J
Epidemiol. 1993;137:959–965.
7. Hanson RL, Pratley RE, Bogardus C, Narayan KM, Roumain JM, Imperatore G,
Fagot-Campagna A, Pettitt DJ, Bennett PH, Knowler WC. Evaluation of simple
indices of insulin sensitivity and insulin secretion for use in epidemiologic
studies. Am J Epidemiol. 2000;151:190–198.
8. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS. Insulin resistance and
the relationship of a dyslipidemia to coronary heart disease: the Framingham
Heart Study. Arterioscler Thromb Vasc Biol. 2011;31:1208–1214.
9. Lazzeri C, Sori A, Chiostri M, Gensini GF, Valente S. Prognostic role of
insulin resistance as assessed by homeostatic model assessment index in
the acute phase of myocardial infarction in nondiabetic patients submitted
to percutaneous coronary intervention. Eur J Anaesthesiol. 2009;26:856–
862.
10. Ausk KJ, Boyko EJ, Ioannou GN. Insulin resistance predicts mortality in
nondiabetic individuals in the U.S. Diabetes Care. 2010;33:1179–1185.
11. Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN,
Baumgartner KB, Bernstein L, Ballard-Barbash R. Fasting C-peptide levels and
death resulting from all causes and breast cancer: the health, eating, activity,
and lifestyle study. J Clin Oncol. 2011;29:47–53.
12. Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF. The metabolism
of proinsulin and insulin by the liver. J Clin Invest. 1972;51:912–921.
13. Matthews DR, Rudenski AS, Burnett MA, Darling P, Turner RC. The half-life of
endogenous insulin and C-peptide in man assessed by somatostatin suppres-
sion. Clin Endocrinol (Oxf). 1985;23:71–79.
14. Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the
biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulin-
ism. Eur J Endocrinol. 2007;157:75–83.
15. National Center for Health Statistics, Centers for Disease Control and
Prevention. Analytic and Reporting Guidelines: The Third National Health and
Nutrition Examination Survey, NHANES III (1988–1994): Linked Mortality File
Public-use. Available at: http://www.cdc.gov/nchs/data/datalinkage/
nh3_ﬁle_layout_public_2010.pdf. Accessed September 30, 2011.
16. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon
MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund
KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland
DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB,
McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G,
Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong
ND, Wylie-Rosett J. Heart disease and stroke statistics: 2011 update.
Circulation. 2011;123:e18–e209.
17. The Third National Health and Nutrition Examination Survey, NHANES III
(1988–1994): laboratory data ﬁle documentation. (Accessed September 30,
2011 at fttp://ftp.cdc.gov/pub/Health_Statistics/NCHS/nhanes/nhanes3/
1A/lab-acc.pdf.)
18. U.S. Department of Health and Human Services. Laboratory procedures used
for the Third National Health and Nutrition Examination Survey (NHANES 3),
1988–1994. Available at: http://www.cdc.gov/nchs/data/nhanes/nhan
es3/cdrom/NCHS/MANUALS/LABMAN.PDF. Accessed September 30, 2011.
19. Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N,
Urabe A. Alcohol consumption is inversely correlated with insulin resistance,
independent of metabolic syndrome factors and fatty liver diseases. J Clin
Gastroenterol. 2011;45:808–813.
20. Ingelsson E, Arnlov J, Sundstrom J, Riserus U, Michaelsson K, Byberg L.
Relative importance and conjoint effects of obesity and physical inactivity for
the development of insulin resistance. Eur J Cardiovasc Prev Rehabil. 2009;
16:28–33.
21. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E,
Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S,
Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes
mellitus, fasting blood glucose concentration, and risk of vascular disease: a
collaborative meta-analysis of 102 prospective studies. Lancet.
2010;375:2215–2222.
22. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh
J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in
nondiabetic adults. N Engl J Med. 2010;362:800–811.
23. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular ﬁltration rate from serum creatinine: a new
prediction equation. Modiﬁcation of diet in renal disease study Group. Ann
Intern Med. 1999;130:461–470.
24. Vlek AL, van der Graaf Y, Spiering W, Algra A, Visseren FL. Cardiovascular
events and all-cause mortality by albuminuria and decreased glomerular
ﬁltration rate in patients with vascular disease. J Intern Med. 2008;264:351–
360.
25. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino
RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease
events in nonhypertensive and nondiabetic individuals: the Framingham Heart
Study. Circulation. 2005;112:969–975.
26. Ridker PM, Rifai N, Clearﬁeld M, Downs JR, Weis SE, Miles JS, Gotto AM Jr.
Measurement of C-reactive protein for the targeting of statin therapy in the
primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–
1965.
27. Goswami B, Tayal D, Tyagi S, Mallika V. Assessment of insulin resistance,
dyslipidemia and inﬂammatory response in North Indian male patients with
angiographically proven coronary artery disease. Minerva Cardioangiol. 2011;
59:139–147.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem. 1972;18:499–502.
29. Mohadjer L, Montaquila J, Bell B, James P, Flores-Cervantes I, Montes M,
Waksberg J, eds. National Health and Nutrition Examination Survey III: Weighting
and Examination Methodology. Hyattsville, MD: National Center for Health
Statistics; 1996. Available at: http://archive.nlm.nih.gov/proj/dxpnet/
nhanes/docs/doc/nhanes_analysis/wgt_exec.pdf. Accessed September 30,
2011.
30. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, Hori
Y, Yano Y, Adachi Y. Homeostasis model assessment is a reliable indicator of
insulin resistance during follow-up of patients with type 2 diabetes. Diabetes
Care. 2001;24:362–365.
31. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ.
Quantitative insulin sensitivity check index: a simple, accurate method for
assessing insulin sensitivity in humans. J Clin Endocrinol Metab.
2000;85:2402–2410.
32. Korn EL, Graubard BI. Analysis of Health Surveys. New York: John Wiley & Sons,
Inc.; 1999.
33. Hosmer JDW, Lemeshow S. Chapter 6: assessment of model adequacy. In:
Cressie NAC, Fisher NI, Johnstone IM, Kadane JB, Scott DW, et al. eds. Applied
Survival Analysis: regression Modeling of Time to Event Data: regression
Modeling of Time to Event Data. New York: John Wiley & Sons; 1999:
203–222.
34. Greenland S, Rothman KJ. Measures of effect and measures of association. In:
Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia, PA:
Lippincott Williams & Wilkins; 1998:53–55.
35. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: John
Wiley & Sons, Inc.; 1987.
36. Rubin DB, Schenker N. Multiple imputation in health-care databases: an
overview and some applications. Stat Med. 1991;10:585–598.
37. Multiple-imputation analysis using STATA’s MI command. STATA Corp., 2010.
Available at: http://www.stata.com/meeting/boston10/boston10_march-
enko.pdf. Accessed October 10, 2012.
38. Li K, Raghunathan T, Rubin D. Large-sample signiﬁcance levels from multiply
imputed data using moment-based statistics and an F reference distribution.
J Am Stat Assoc. 1991;86:1065–1073.
39. Lithell H, Sundstrom J, Arnlov J, Bjorklund K, Hanni A, Hedman A, Zethelius B,
Byberg L, Kilander L, Reneland R. Epidemiological and clinical studies on
insulin resistance and diabetes. Ups J Med Sci. 2000;105:135–150.
DOI: 10.1161/JAHA.112.003152 Journal of the American Heart Association 11
C-Peptide and CVD Death Patel et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2018
40. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N.
Insulin- and obesity-related variables in early-stage breast cancer: correla-
tions and time course of prognostic associations. J Clin Oncol. 2012;30:
164–171.
41. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom
AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study.
Ann Epidemiol. 2008;18:671–677. PMCID: 2566531.
42. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and
glucose levels and breast cancer incidence: the atherosclerosis risk in
communities study. Am J Epidemiol. 2002;156:349–352.
43. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular
risk factors in conﬁrmed prediabetic individuals. JAMA. 1990;263:2893–2898.
44. Wong CY, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH.
Alterations of left ventricular myocardial characteristics associated with
obesity. Circulation. 2004;110:3081–3087.
45. Potenza MA, Montagnani M. Abnormal insulin signaling: early detection of
silent coronary artery disease-erectile dysfunction? Curr Pharm Des.
2008;14:3737–3748.
46. Karatela RA, Sainani GS. Interrelationships of Factor VII activity and plasma
leptin with insulin resistance in coronary heart disease. Atherosclerosis.
2010;209:235–240.
47. Varol E, Akcay S, Ozaydin M, Erdogan D, Dogan A, Altinbas A. Mean platelet
volume is associated with insulin resistance in non-obese, non-diabetic
patients with coronary artery disease. J Cardiol. 2010;56:154–158.
48. Banerjee D, Recio-Mayoral A, Chitalia N, Kaski JC. Insulin resistance,
inﬂammation, and vascular disease in nondiabetic predialysis chronic kidney
disease patients. Clin Cardiol. 2011;34:360–365.
49. Chauveau P, Rigalleau V, Aparicio M. Insulin resistance and chronic kidney
disease. Nephrol Ther. 2008;4:568–574.
50. Gobal F, Deshmukh A, Shah S, Mehta JL. Triad of metabolic syndrome,
chronic kidney disease, and coronary heart disease with a focus on
microalbuminuria death by overeating. J Am Coll Cardiol. 2011;57:2303–
2308.
51. Cheng WS, Wingard DL, Kritz-Silverstein D, Barrett-Connor E. Sensitivity of
death certiﬁcate data for monitoring diabetes mortality–diabetic eye disease
follow-up study, 1985–1990. MMWR Morb Mortal Wkly Rep. 1991;40:739–
741.
52. Cheng WS, Wingard DL, Kritz-Silverstein D, Barrett-Connor E. Sensitivity and
speciﬁcity of death certiﬁcates for diabetes: as good as it gets? Diabetes Care.
2008;31:279–284.
53. Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the
death certiﬁcate. N Engl J Med. 1985;313:1263–1269.
DOI: 10.1161/JAHA.112.003152 Journal of the American Heart Association 12
C-Peptide and CVD Death Patel et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2018
